Genetic evidence shows RACGAP1 contributes to survival signaling in lung adenocarcinoma, suggesting it as a therapeutic target.
This study presents genetic evidence supportive of a causal contribution of RACGAP1 to LUAD, highlighting it as a promising prognostic biomarker and candidate therapeutic target. By delineating a RACGAP1-driven axis that coordinates survival signaling and suppresses tumor surveillance, our findings highlight RACGAP1 as a promising therapeutic target for novel adjuvant strategies.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: